In summary, our data demonstrate that combining PI3K inhibitors with EZH1/2 inhibitors may be a promising therapeutic regimen for AML patients, especially for depleting leukemia-initiating cells to reduce the rate of relapse. The gene discussed is PIK3CB; the disease is acute myeloid leukemia.